Context Therapeutics Inc is trading 10.84% down at $1.81 as broader market pressure weighs heavily on the biotechnology sector.
- The move appears tied to a wider selloff in growth and biotech names as the Nasdaq falls and interest rate expectations turn more hawkish.
- No major company announcements, earnings updates, or FDA-related events have been identified to account for the move.
- The stock is extending a sharp multi-day slide, continuing a downtrend that suggests broader market sentiment is driving the selling pressure rather than company-specific news.